Nippon Shinyaku Co., Ltd. (NPPNY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nippon Shinyaku Co., Ltd. (NPPNY) trades at $6.00 with AI Score 58/100 (Grade B). Nippon Shinyaku Co. , Ltd. is a Japanese pharmaceutical company focused on manufacturing and selling drugs and functional foods internationally. Market cap: $1.62B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for NPPNY: NPPNY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NPPNY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NPPNY: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Nippon Shinyaku Co., Ltd. (NPPNY) Healthcare & Pipeline Overview
Nippon Shinyaku Co., Ltd., founded in 1911, is a Japanese pharmaceutical company specializing in niche therapeutic areas like urology, hematology, and pulmonary arterial hypertension, complemented by a functional foods segment. The company maintains a strong presence in Japan and expands internationally, evidenced by a 67.3% gross margin and a 2.37% dividend yield.
What Is the Investment Thesis for NPPNY?
Nippon Shinyaku Co., Ltd. presents a compelling investment case based on its established presence in niche pharmaceutical markets and its diversified product portfolio. With a P/E ratio of 11.84 and a profit margin of 18.0%, the company demonstrates financial stability and profitability. The company's focus on specialized therapeutic areas, such as urology and hematology, provides a degree of insulation from broader market pressures. Growth catalysts include the expansion of its international presence and the potential for new drug approvals in its pipeline. However, investors should be aware of potential risks, including regulatory challenges and competition from larger pharmaceutical companies. The company's dividend yield of 2.37% offers an additional incentive for long-term investors.
Based on FMP financials and quantitative analysis
NPPNY Key Highlights
- Market capitalization of $1.62B, reflecting its established position in the pharmaceutical industry.
- P/E ratio of 11.84, suggesting a potentially undervalued stock compared to its earnings.
- Profit margin of 18.0%, indicating strong profitability and efficient operations.
- Gross margin of 67.3%, highlighting the company's ability to maintain high product pricing and manage costs effectively.
- Dividend yield of 2.37%, providing a steady income stream for investors.
Who Are NPPNY's Competitors?
NPPNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $0.16 | +0.00% | $821.34M | 44 |
| CMOPF Cosmo Pharmaceuticals N.V. | $82.60 | +0.67% | $1.41B | 49 |
| EVOTF Evotec SE | $6.69 | +0.00% | $1.19B | 45 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $0.84 | +0.00% | $818.18M | 52 |
| GTBIF Green Thumb Industries Inc. | $7.60 | +0.00% | $1.77B | 57 |
| ALVO Alvotech | $3.61 | +0.84% | $1.22B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NPPNY's Key Strengths?
- Strong presence in niche pharmaceutical markets
- Diversified product portfolio
- Established research and development capabilities
- High gross margin
What Are NPPNY's Weaknesses?
- Limited geographic presence outside of Japan
- Dependence on a few key products
- Exposure to regulatory risks
- Smaller scale compared to major pharmaceutical companies
What Could Drive NPPNY Stock Higher?
- Potential FDA/EMA approval for new drug candidates in the pipeline.
- Expansion of sales and marketing efforts in international markets.
- Strategic partnerships and collaborations with other pharmaceutical companies.
What Are the Key Risks for NPPNY?
- Regulatory setbacks or delays in drug approvals.
- Competition from generic drugs and biosimilars.
- Currency fluctuations affecting the value of ADRs.
- Dependence on key products and therapeutic areas.
What Are the Growth Opportunities for NPPNY?
- Expansion of International Sales: Nippon Shinyaku has the opportunity to expand its sales and marketing efforts in international markets, particularly in Europe and Asia. By leveraging its existing product portfolio and establishing strategic partnerships, the company can tap into new customer bases and increase its revenue streams. The global market for pharmaceuticals is projected to reach $1.7 trillion by 2025, offering significant growth potential.
- New Drug Development and Approvals: Investing in research and development to bring new drugs to market is a critical growth driver for Nippon Shinyaku. The company can focus on developing innovative therapies for unmet medical needs in its key therapeutic areas, such as urology and hematology. Successful drug approvals can lead to significant revenue growth and increased market share. The timeline for drug development and approval can range from 5 to 10 years.
- Strategic Acquisitions and Partnerships: Nippon Shinyaku can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring smaller companies with complementary products or technologies, the company can accelerate its growth and diversify its revenue streams. Partnerships with other pharmaceutical companies can also provide access to new markets and expertise. The pharmaceutical M&A market is expected to remain active, providing opportunities for growth.
- Focus on Functional Foods Market: The functional foods market is experiencing strong growth, driven by increasing consumer awareness of the health benefits of functional foods. Nippon Shinyaku can capitalize on this trend by expanding its product offerings and marketing efforts in the functional foods segment. This diversification can provide a stable revenue stream and reduce the company's reliance on pharmaceuticals. The global functional foods market is projected to reach $278 billion by 2027.
- Development of Personalized Medicine: The trend towards personalized medicine is creating new opportunities for pharmaceutical companies to develop targeted therapies based on individual patient characteristics. Nippon Shinyaku can invest in research and development to develop personalized medicine products for its key therapeutic areas. This can lead to more effective treatments and increased patient satisfaction. The personalized medicine market is expected to grow rapidly in the coming years.
What Opportunities Does NPPNY Have?
- Expansion into new international markets
- Development of new drugs and therapies
- Strategic acquisitions and partnerships
- Growth in the functional foods market
What Threats Does NPPNY Face?
- Competition from larger pharmaceutical companies
- Generic erosion of key products
- Changes in healthcare regulations
- Economic downturns
What Are NPPNY's Competitive Advantages?
- Specialized product portfolio in niche therapeutic areas.
- Established presence in the Japanese pharmaceutical market.
- Strong research and development capabilities.
- Diversified revenue streams from pharmaceuticals and functional foods.
What Does NPPNY Do?
Nippon Shinyaku Co., Ltd., established in 1911 and headquartered in Kyoto, Japan, is a pharmaceutical company engaged in the manufacture and sale of pharmaceuticals and functional foods across Japan, Switzerland, and other international markets. The company operates through two primary segments: Pharmaceuticals and Functional Food. Its pharmaceutical offerings encompass a wide range of therapeutic areas, including urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. Key products include Zalutia for urinary disorders, Eviprostat for prostatic hypertrophy, and Cialis for erectile dysfunction. In hematology, Nippon Shinyaku offers Vidaza for myelodysplastic syndrome and Trisenox for acute promyelocytic leukemia. The company also provides treatments for pulmonary arterial hypertension, such as Uptravi and Adcirca. Beyond pharmaceuticals, Nippon Shinyaku's Functional Food segment provides health food ingredients, preservatives, protein preparations, supplements, spices, and condiments. The company is also actively involved in research and development, focusing on gynecology, otorhinolaryngology, and orthopedics, aiming to expand its product pipeline and address unmet medical needs.
What Products and Services Does NPPNY Offer?
- Manufactures and sells pharmaceuticals for urological diseases.
- Develops and markets drugs for hematologic malignancies.
- Offers treatments for cardiovascular and metabolic diseases.
- Provides medications for gastrointestinal disorders.
- Researches and develops drugs in gynecology, otorhinolaryngology, and orthopedics.
- Produces and sells functional foods, including health food ingredients and supplements.
How Does NPPNY Make Money?
- Develops and manufactures pharmaceutical products.
- Markets and sells drugs through its own sales force and distribution network.
- Generates revenue from the sale of pharmaceuticals and functional foods.
- Invests in research and development to create new products.
What Industry Does NPPNY Operate In?
Nippon Shinyaku Co., Ltd. operates within the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market for specialty and generic drugs is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The company's focus on niche therapeutic areas allows it to compete effectively against larger pharmaceutical companies. Competitors include CHIZF (Chiesi Farmaceutici S.p.A.), CMOPF (CMO Group Public Company Limited), EVOTF (Evotec SE), GNMLF (Genmab A/S), and GTBIF (GT Biopharma, Inc.).
Who Are NPPNY's Key Customers?
- Hospitals and clinics.
- Pharmacies and drugstores.
- Patients with urological, hematological, and cardiovascular diseases.
- Consumers seeking health food ingredients and supplements.
How Nippon Shinyaku Co., Ltd. Is Valued
Nippon Shinyaku Co., Ltd. carries a market capitalization of $1.62B, placing it in the small-cap category. Relative to its peer group, NPPNY's quantitative score of 58/100 is roughly in line with the peer average of 49/100.
Company Profile
Nippon Shinyaku Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kyoto, JP. The company is led by CEO Toru Nakai. NPPNY has traded publicly since 2016.
ROE 11%Key Financial Metrics
Return on equity for Nippon Shinyaku Co., Ltd. stands at 10.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.6%, showing how much profit it generates from its asset base. NPPNY trades at a trailing price-to-earnings ratio of 9.26, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Nippon Shinyaku Co., Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.17 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Nippon Shinyaku Co., Ltd. revenue of about $169.43B for fiscal 2026, with EPS near $0.00. The estimate reflects 7 contributing analysts.
NPPNY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Strong presence in niche pharmaceutical markets
- Diversified product portfolio
- Established research and development capabilities
- High gross margin
Bear Case
- Limited geographic presence outside of Japan
- Dependence on a few key products
- Exposure to regulatory risks
- Smaller scale compared to major pharmaceutical companies
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NPPNY Latest News
No recent news available for NPPNY.
NPPNY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NPPNY.
Price Targets
Wall Street price target analysis for NPPNY.
NPPNY MoonshotScore
What does this score mean?
The MoonshotScore rates NPPNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Toru Nakai
CEO
Toru Nakai serves as the CEO of Nippon Shinyaku Co., Ltd. His professional background and specific career history prior to his role at Nippon Shinyaku are not detailed in the provided information. As CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving its growth initiatives. He manages a workforce of 2213 employees.
Track Record: Due to limited information, specific achievements and strategic decisions under Toru Nakai's leadership cannot be detailed. However, as CEO, he is responsible for maintaining the company's profitability, expanding its product portfolio, and navigating the competitive pharmaceutical landscape.
Nippon Shinyaku Co., Ltd. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Nippon Shinyaku (NPPNY), each ADR represents a certain number of shares of Nippon Shinyaku's stock traded on its home market in Japan. This allows U.S. investors to invest in Nippon Shinyaku without dealing with foreign exchanges.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: NPPN
NPPNY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Nippon Shinyaku (NPPNY) has the least stringent listing requirements and may not be fully compliant with U.S. reporting standards. Trading on the OTC Other tier carries more risk compared to stocks listed on major exchanges like the NYSE or NASDAQ, as there is generally less transparency and regulatory oversight. Companies on this tier may have limited financial disclosure, making it harder for investors to assess their financial health and prospects.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Wider bid-ask spreads
- Potential for price manipulation
- Higher risk of fraud or scams
- Verify the company's registration and legal status
- Obtain and review available financial statements
- Research the company's management team and their track record
- Assess the company's business model and competitive landscape
- Understand the risks associated with investing in OTC stocks
- Consult with a financial advisor
- Be cautious of unsolicited investment offers
- Established operating history since 1911
- Presence in the pharmaceutical industry
- Home market listing on the Tokyo Stock Exchange
- Positive gross and profit margins
Nippon Shinyaku Co., Ltd. Healthcare Stock: Key Questions Answered
What does Nippon Shinyaku Co., Ltd. do?
Nippon Shinyaku Co., Ltd. is a pharmaceutical company that manufactures and sells drugs and functional foods. The company's pharmaceutical segment focuses on niche therapeutic areas such as urology, hematology, and pulmonary arterial hypertension. Its functional food segment provides health food ingredients, supplements, and other products. The company operates primarily in Japan, with a growing international presence. Nippon Shinyaku aims to address unmet medical needs and improve patient outcomes through its innovative products and research and development efforts.
What are the main risks for NPPNY?
Nippon Shinyaku Co., Ltd. faces several risks, including regulatory challenges, competition from generic drugs, and currency fluctuations. The company's success depends on its ability to obtain regulatory approvals for its drug candidates and to protect its intellectual property. Competition from generic drugs can erode the company's market share and profitability. As an ADR, NPPNY is also subject to currency risk, which can affect the value of the investment for U.S. investors.
What are the key factors to evaluate for NPPNY?
Nippon Shinyaku Co., Ltd. (NPPNY) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does NPPNY data refresh on this page?
NPPNY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NPPNY's recent stock price performance?
Nippon Shinyaku Co., Ltd. (NPPNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong presence in niche pharmaceutical markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NPPNY overvalued or undervalued right now?
Valuing Nippon Shinyaku Co., Ltd. (NPPNY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NPPNY?
Before investing in Nippon Shinyaku Co., Ltd. (NPPNY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NPPNY to a portfolio?
Key strength of Nippon Shinyaku Co., Ltd. (NPPNY): Strong presence in niche pharmaceutical markets. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for NPPNY, which may provide additional insights.